| Code | Description | Claims | Beneficiaries | Total Paid |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
71,171 |
62,450 |
$10.89M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
44,281 |
37,734 |
$7.05M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
36,931 |
31,489 |
$6.41M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
44,171 |
40,002 |
$5.68M |
| 71045 |
Radiologic examination, chest; single view |
33,598 |
28,804 |
$4.76M |
| 99218 |
|
12,275 |
5,351 |
$4.25M |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
5,748 |
2,413 |
$3.98M |
| J9271 |
Injection, pembrolizumab, 1 mg |
660 |
367 |
$2.97M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
39,163 |
33,698 |
$2.65M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
20,733 |
4,097 |
$1.99M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
22,261 |
19,450 |
$1.56M |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
22,793 |
19,955 |
$1.48M |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
12,740 |
11,262 |
$1.44M |
| 99221 |
|
3,117 |
1,684 |
$1.34M |
| 59025 |
Fetal non-stress test |
4,250 |
2,701 |
$1.17M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
2,724 |
2,345 |
$1.01M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
7,467 |
4,376 |
$893K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
6,691 |
4,956 |
$855K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
34,805 |
28,764 |
$807K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
4,179 |
1,732 |
$775K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
36,793 |
30,229 |
$719K |
| 70450 |
Computed tomography, head or brain; without contrast material |
7,196 |
6,061 |
$709K |
| 71046 |
Radiologic examination, chest; 2 views |
8,608 |
7,495 |
$704K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
607 |
491 |
$676K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,807 |
5,143 |
$656K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
137,011 |
104,068 |
$570K |
| J2323 |
Injection, natalizumab, 1 mg |
100 |
90 |
$524K |
| 80053 |
Comprehensive metabolic panel |
89,402 |
73,982 |
$507K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
10,164 |
5,706 |
$488K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
15,548 |
13,741 |
$419K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
15,549 |
13,741 |
$419K |
| J0897 |
Injection, denosumab, 1 mg |
1,174 |
883 |
$417K |
| 80050 |
General health panel |
2,307 |
2,165 |
$381K |
| 36415 |
Collection of venous blood by venipuncture |
185,857 |
133,353 |
$354K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
6,882 |
4,309 |
$352K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
260 |
224 |
$290K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
585 |
497 |
$289K |
| 84484 |
|
31,066 |
19,846 |
$205K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
9,223 |
8,214 |
$195K |
| J1756 |
Injection, iron sucrose, 1 mg |
3,731 |
1,694 |
$189K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
420 |
380 |
$176K |
| 99217 |
|
952 |
262 |
$160K |
| 96367 |
|
3,076 |
1,225 |
$158K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
9,499 |
8,627 |
$156K |
| 81025 |
|
31,554 |
27,490 |
$156K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
11,317 |
9,315 |
$150K |
| 96417 |
|
1,375 |
677 |
$143K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
820 |
659 |
$135K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
28,442 |
22,827 |
$122K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,039 |
880 |
$121K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
22,109 |
17,214 |
$121K |
| 96415 |
|
1,276 |
460 |
$115K |
| 80061 |
Lipid panel |
11,579 |
10,539 |
$105K |
| J3111 |
Injection, romosozumab-aqqg, 1 mg |
205 |
187 |
$105K |
| 73562 |
|
2,157 |
1,444 |
$94K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
1,777 |
1,247 |
$90K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
590 |
552 |
$88K |
| 80074 |
|
1,978 |
1,774 |
$78K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,616 |
1,303 |
$70K |
| 81001 |
|
34,388 |
29,350 |
$65K |
| 64483 |
|
170 |
120 |
$63K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
8,709 |
8,024 |
$60K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
5,498 |
4,879 |
$60K |
| 83735 |
|
15,375 |
12,955 |
$59K |
| 83690 |
|
17,963 |
15,253 |
$59K |
| 84443 |
Thyroid stimulating hormone (TSH) |
6,275 |
5,594 |
$59K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,870 |
1,515 |
$57K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
191 |
177 |
$57K |
| 82607 |
|
6,472 |
5,893 |
$55K |
| 97161 |
|
460 |
349 |
$53K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
376 |
316 |
$52K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,843 |
3,081 |
$50K |
| 73565 |
|
1,202 |
1,100 |
$47K |
| 82728 |
|
6,185 |
5,600 |
$46K |
| 82746 |
|
5,643 |
5,112 |
$46K |
| 84466 |
|
6,314 |
5,675 |
$44K |
| 83880 |
|
2,201 |
1,828 |
$43K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,183 |
1,009 |
$43K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
1,594 |
1,467 |
$42K |
| 99215 |
Prolong outpt/office vis |
379 |
360 |
$41K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
67 |
64 |
$38K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,684 |
3,235 |
$38K |
| 86703 |
|
3,200 |
2,927 |
$37K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
212 |
188 |
$35K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
905 |
789 |
$33K |
| 93017 |
|
183 |
160 |
$33K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
44 |
37 |
$31K |
| 43235 |
|
13 |
13 |
$30K |
| 71047 |
|
1,142 |
623 |
$28K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
15 |
13 |
$28K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
6,504 |
5,548 |
$27K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
443 |
417 |
$27K |
| 76830 |
Ultrasound, transvaginal |
149 |
139 |
$26K |
| 11045 |
|
106 |
38 |
$26K |
| 73130 |
|
575 |
474 |
$25K |
| 84702 |
|
3,004 |
2,500 |
$24K |
| 83550 |
|
2,971 |
2,838 |
$24K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
588 |
551 |
$24K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
126 |
104 |
$22K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
194 |
185 |
$21K |
| 11043 |
|
44 |
12 |
$20K |
| 73630 |
|
480 |
396 |
$20K |
| 86704 |
|
1,929 |
1,732 |
$20K |
| 76820 |
|
481 |
284 |
$19K |
| 96411 |
|
364 |
113 |
$18K |
| 86706 |
|
1,958 |
1,761 |
$18K |
| 72100 |
|
1,060 |
885 |
$18K |
| 87631 |
|
120 |
104 |
$15K |
| 77336 |
|
101 |
43 |
$14K |
| 86696 |
|
887 |
783 |
$14K |
| 87070 |
|
2,239 |
1,914 |
$14K |
| 86300 |
|
1,143 |
1,013 |
$13K |
| 73110 |
|
214 |
170 |
$13K |
| 86592 |
|
3,643 |
3,329 |
$13K |
| 76801 |
|
75 |
68 |
$12K |
| 73030 |
|
347 |
277 |
$12K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
283 |
245 |
$12K |
| 82378 |
|
1,119 |
973 |
$11K |
| 84439 |
|
1,875 |
1,660 |
$10K |
| 86695 |
|
927 |
821 |
$10K |
| 95885 |
|
35 |
33 |
$10K |
| 83655 |
|
745 |
703 |
$9K |
| 86803 |
|
747 |
690 |
$9K |
| 86694 |
|
731 |
635 |
$9K |
| 84703 |
|
1,553 |
1,326 |
$8K |
| 87210 |
|
2,543 |
2,231 |
$8K |
| 72082 |
|
116 |
99 |
$7K |
| 80081 |
|
118 |
98 |
$7K |
| 80069 |
|
1,821 |
1,532 |
$7K |
| 97162 |
|
84 |
65 |
$7K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
1,161 |
493 |
$6K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
15 |
14 |
$6K |
| 72040 |
|
130 |
106 |
$6K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
401 |
306 |
$5K |
| 97116 |
|
1,241 |
415 |
$5K |
| 81003 |
|
3,894 |
3,338 |
$5K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
29 |
27 |
$5K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
43 |
40 |
$4K |
| 73610 |
|
119 |
105 |
$4K |
| 82784 |
|
466 |
265 |
$4K |
| 99205 |
Prolong outpt/office vis |
49 |
42 |
$4K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
65 |
55 |
$4K |
| J2785 |
Injection, regadenoson, 0.1 mg |
74 |
67 |
$3K |
| 86003 |
|
26 |
22 |
$3K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
714 |
194 |
$3K |
| 73523 |
|
42 |
38 |
$3K |
| 72110 |
|
45 |
44 |
$3K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
96 |
95 |
$3K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
24 |
24 |
$3K |
| 73502 |
|
55 |
51 |
$2K |
| 73560 |
|
68 |
50 |
$2K |
| J9267 |
Injection, paclitaxel, 1 mg |
155 |
50 |
$2K |
| 76881 |
|
13 |
12 |
$2K |
| 83605 |
|
317 |
257 |
$2K |
| 95910 |
|
15 |
14 |
$2K |
| 82977 |
|
388 |
365 |
$2K |
| 83615 |
|
536 |
446 |
$2K |
| 83883 |
|
162 |
110 |
$2K |
| 73564 |
|
35 |
30 |
$2K |
| 85660 |
|
309 |
270 |
$1K |
| 86334 |
|
133 |
114 |
$1K |
| 83970 |
|
99 |
81 |
$1K |
| 76821 |
|
16 |
12 |
$1K |
| 84480 |
|
122 |
115 |
$1K |
| Q9969 |
Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose |
106 |
92 |
$1K |
| 85379 |
|
166 |
141 |
$1K |
| 82248 |
|
230 |
221 |
$1K |
| 84550 |
|
390 |
365 |
$1K |
| J9045 |
Injection, carboplatin, 50 mg |
117 |
63 |
$1K |
| 73140 |
|
20 |
15 |
$1K |
| J9190 |
Injection, fluorouracil, 500 mg |
307 |
109 |
$1K |
| J2916 |
Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg |
76 |
47 |
$927.20 |
| 77417 |
|
32 |
13 |
$859.68 |
| 82570 |
|
265 |
251 |
$850.91 |
| 82043 |
|
250 |
239 |
$797.19 |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
168 |
57 |
$745.84 |
| 84153 |
|
52 |
48 |
$681.78 |
| 72170 |
|
25 |
24 |
$679.83 |
| 85610 |
|
475 |
307 |
$675.84 |
| 84156 |
|
264 |
250 |
$664.04 |
| 86850 |
|
126 |
115 |
$622.88 |
| 86901 |
|
377 |
293 |
$602.81 |
| 86900 |
|
378 |
293 |
$602.49 |
| 84481 |
|
66 |
62 |
$595.93 |
| 84165 |
|
128 |
107 |
$576.41 |
| G0008 |
Administration of influenza virus vaccine |
53 |
44 |
$510.21 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
31,597 |
26,143 |
$466.18 |
| 85730 |
|
143 |
118 |
$463.18 |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
712 |
597 |
$416.78 |
| 82785 |
|
26 |
22 |
$378.58 |
| 85027 |
|
75 |
69 |
$368.79 |
| 82533 |
|
28 |
25 |
$316.07 |
| 84100 |
|
87 |
78 |
$294.05 |
| 86756 |
|
47 |
43 |
$283.32 |
| 97010 |
|
89 |
13 |
$277.30 |
| 86038 |
|
44 |
40 |
$256.61 |
| 92133 |
|
22 |
14 |
$247.77 |
| 82950 |
|
66 |
63 |
$245.89 |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
583 |
497 |
$243.40 |
| 83721 |
|
113 |
101 |
$225.21 |
| 85045 |
|
119 |
80 |
$222.38 |
| 85007 |
|
76 |
70 |
$220.40 |
| J3490 |
Unclassified drugs |
309 |
263 |
$203.09 |
| 87110 |
|
17 |
15 |
$184.32 |
| 82962 |
|
102 |
88 |
$181.85 |
| 85652 |
|
164 |
133 |
$180.20 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
3,936 |
2,078 |
$170.82 |
| 87040 |
|
13 |
12 |
$144.48 |
| 82330 |
|
38 |
31 |
$122.26 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
11,798 |
6,101 |
$119.14 |
| 87081 |
|
33 |
27 |
$109.69 |
| 84436 |
|
20 |
14 |
$105.06 |
| 87340 |
|
12 |
12 |
$93.17 |
| 86140 |
|
34 |
26 |
$90.52 |
| 96368 |
|
1,397 |
574 |
$73.71 |
| 82565 |
|
34 |
25 |
$73.68 |
| 80051 |
|
18 |
12 |
$64.68 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,408 |
1,170 |
$61.35 |
| 84520 |
|
32 |
27 |
$60.08 |
| 82652 |
|
12 |
12 |
$46.10 |
| J2704 |
Injection, propofol, 10 mg |
5,088 |
3,970 |
$41.31 |
| 87176 |
|
26 |
15 |
$35.20 |
| 90661 |
|
12 |
12 |
$25.26 |
| 90653 |
|
21 |
16 |
$25.26 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
12,675 |
9,660 |
$15.17 |
| J2060 |
Injection, lorazepam, 2 mg |
15 |
14 |
$12.47 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
4,759 |
2,892 |
$4.64 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,530 |
1,027 |
$2.90 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
487 |
245 |
$2.53 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
3,073 |
2,074 |
$0.00 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
2,927 |
2,150 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
785 |
503 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
2,254 |
1,765 |
$0.00 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
1,043 |
871 |
$0.00 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
1,184 |
976 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
335 |
266 |
$0.00 |
| 90674 |
|
33 |
30 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
42 |
36 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
107 |
91 |
$0.00 |
| A9270 |
Non-covered item or service |
221 |
153 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
64 |
51 |
$0.00 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
29 |
24 |
$0.00 |
| 88342 |
|
153 |
141 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
14 |
12 |
$0.00 |
| 96376 |
|
18 |
13 |
$0.00 |
| J1790 |
Injection, droperidol, up to 5 mg |
27 |
24 |
$0.00 |
| 90715 |
|
33 |
26 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
527 |
365 |
$0.00 |
| J1644 |
Injection, heparin sodium, per 1000 units |
84 |
36 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
681 |
509 |
$0.00 |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
12 |
12 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
92 |
75 |
$0.00 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
438 |
67 |
$0.00 |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
258 |
87 |
$0.00 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
23 |
13 |
$0.00 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
25 |
14 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
24 |
14 |
$0.00 |
| 76942 |
|
27 |
25 |
$0.00 |
| S0028 |
Injection, famotidine, 20 mg |
32 |
28 |
$0.00 |
| 76937 |
|
17 |
12 |
$0.00 |